Background {#Sec1}
==========

In vitro fertilization (IVF) coupled with embryo transfer into uterus has been applied as treatment for infertility several decades. IVF was initially used to assist the reproduction of sub-fertile women caused by tubal factors \[[@CR1]\]. With the improvement of IVF techniques, IVF is now a routine treatment for many reproductive diseases. However, the success rate of pregnancy is still a problem in clinical IVF practice, which is only about 50% even if the embryos with normal morphology were used for transfer \[[@CR2]\]. In order to select embryos with the best potential good for IVF outcome, morphological assessments of blastocyst and blastocoels have been adopted, but it was still difficult to predict the quality of embryos \[[@CR3]\]. Therefore, it was necessary to develop new strategies for embryo quality evaluation. Epidemiologic investigations showed that many intrinsic and extrinsic factors contributed to the quality of embryo. Because oocyte quality directly influences embryo development, HFF (microenvironment of oocyte maturation) became a main factor contributing to the success of IVF treatment \[[@CR4]\].

Small antral follicles respond to ovarian stimulation by increasing in size due to rapid accumulation of follicular fluid, as well as granulosa cell divisions, which necessitate follicular basal lamina expansion. The components of HFF had several origins: secretions from granulosa cells, thecal cells, occytes, and blood plasma composition transferred through the thecal capillaries \[[@CR5]\]. The major components of HFF were proteins \[[@CR6]\], steroid hormones \[[@CR7]\], and metabolites \[[@CR8]\]. HFF provided a special milieu to facilitate the communications between occyte and follicular cells, the development of follicle and the maturation of occytes. The alteration of HFF proteins reflected disorders of main secretary function of granulosa cells and thecae, and the damage of blood follicular barrier, which was associated with abnormal folliculogenesis \[[@CR9]\] and a diminished reproductive potential \[[@CR10]\]. In IVF treatment, HFF was easily accessible during the aspiration of oocytes from follicle, and was an ideal source for noninvasive screening of biomakers for oocyte maturation, fertilization success, IVF outcome, pregnancy, and ovarian diseases.

In the postgenomic era, proteomic techniques have been widely used in the field of reproductive medicine. HFF proteome has become a hotspot for research, which not only contributed to discovering proteins related to IVF outcomes, but also improved our comprehensive understanding of physiological process during follicle development and oocyte maturation \[[@CR11]\]. Li and co-workers used surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS) combined with weak cation-exchange protein chip (WCX-2) to search for differentially expressed HFF proteins from mature and antral follicles \[[@CR12]\]. Two-dimensional gel electrophoresis (2D--GE) followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was also used to identify 8 differentially expressed HFF proteins related to immune and inflammatory responses from controlled ovarian hyperstimulation (COH) and natural ovulatory cycles \[[@CR13]\]. Ambekar and co-workers carried out SDS-PAGE, OFFGEL and SCX-based separation followed by LC-MS/MS analysis to characterize 480 HFF proteins for a better understanding of folliculogenesis physiology \[[@CR14]\]. Chen and co-workers explored the HFF biomarkers between successfully fertilized oocytes and unfertilized mature oocytes through nano-scale liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS), and found 53 peptides to be potential candidates \[[@CR15]\]. Although proteomic researches on HFF deepened our understanding of reproductive process and provided candidates related to oocyte quality, follicle development, IVF outcome and ovarian disorders, it was still essential to fully delineate the HFF networks and pathways involved in the physiology of reproduction and pathophysiology of infertility.

In the present study, we carried out an in-depth proteomic analysis of HFF from women undergoing successful IVF based on dual RP-HPLC coupled to MALDI TOF/TOF MS. The results profiled candidate biomarkers for the prediction of oocyte maturation, fertilization, and pregnancy and provided a new complement for HFF dataset, which will improve the understanding of biological processes and complicated pathways and interaction networks in HFF.

Methods {#Sec2}
=======

Patients enrollment and sample preparation {#Sec3}
------------------------------------------

The HFF samples were collected from 10 women who underwent IVF treatment and achieved pregnancy. The selected patients met the following criteria: infertility not caused by tubal factor; aged less than 38 years; serum FSH values \<12 mIU/mL; undergoing their first fresh egg retrieval cycle; ovulation stimulated with the long protocol. The patients were also without chromosomal abnormalities, polycystic ovary syndrome (PCOS), endometriosis and or endocrine disease. Cause of infertility was simple male factor. The body mass index (BMI) of patients met the normal criteria proposed by WGOC (18.5 ≤ BMI ≤ 23.9 kg/m^2^) \[[@CR16]--[@CR18]\]. Ovarian stimulation and oocyte retrieval were performed as previously described \[[@CR19]\]. Briefly, when more than two follicles exceeded 18 mm in diameter, 10,000 IU of HCG (Merck Serono, Swiss) was injected intramuscular. After 36 h, HFF was collected during trans-vaginal ultrasound guided aspiration of oocytes. The resultant HFF samples were macroscopically clear and without contamination of the flushing medium.

The samples were centrifuged at 10,000×g at 4 °C for 30 min to produce cell debris-free HFF fraction for further analysis. Concentration of HFF was determined by the Bradford method \[[@CR20]\]. This work has been approved by the Ethics Committee of Beijing BaoDao Obstetrics and Gynecology Hospital, and written informed consents were obtained from all participants.

First dimension high pH RP chromatography {#Sec4}
-----------------------------------------

Equal amounts (50μg) of HFF proteins from each sample were pooled for separation. The samples were sequentially treated with 20 mM dithiothreitol at 37 °C for 120 min, and 50 mM iodoacetamide in dark for 60 min at room temperature. Then the sample was finally digested using trypsin (sequencing grade, Promega, France) (*W*/W, 1:50 enzyme/protein) overnight at 37 °C. According to the previous method with appropriate modification \[[@CR21]\], the first dimension RP separation was performed on PF-2D HPLC System (Rigol) by using a Durashell RP column (5 μm, 150 Å, 250 mm × 4.6 mm i.d., Agela). Mobile phases A (2% acetonitrile, adjusted pH to 10.0 using NH~3~.H~2~0) and B (98% acetonitrile, adjusted pH to 10.0 using NH~3~.H~2~0) were used to develop a gradient. The solvent gradient was set as follows: 5% B, 5 min; 5--15% B, 15 min; 15--38% B, 15 min; 38--90% B, 1 min; 90% B, 8.5 min; 90--5% B, 0.5 min; 5% B, 10 min. The tryptic peptides were separated at an eluent flow rate of 0.8 ml/min and monitored at 214 nm. Totally, 28 eluent fractions were collected and dried by a SPD2010 SpeedVac concentrator system (Thermo, USA).

Second dimension low pH RP chromatography coupled with MS/MS measurement {#Sec5}
------------------------------------------------------------------------

According to the previous method \[[@CR22]\], the samples were dried under vacuum and reconstituted in 30 μl of 0.1% (*v*/v) formic acid, 2% (*v*/v) acetonitrile in water for subsequent analyses. Each fraction was separated and spotted using the Tempo™ LC-MALDI Spotting System (AB SCIEX, USA). Peptides were separated by a C18 AQ 150 × 0.2 mm column (3 μm, Michrom, USA) using a linear gradient formed by buffer A (2% acetonitrile, 0.1% formic acid) and buffer B (98% acetonitrile, 0.1% formic acid), from 5% to 35% of buffer B over 90 min at a flow rate of 0.5 μL/min. The eluted peptides were mixed with matrix solution (5 mg/mL in 70% acetonitrile, 0.1% trifluoroacetic acid) at a flow rate of 2 μL/min pushed by additional syringe pump. For each fraction, 616 spots were spotted on a 123× 81 mm LC-MALDI plate insert. Then the spots were analyzed using MALDI-TOF/TOF 5800 mass spectrometer (AB SCIEX, USA). A full-scan MS experiment (m/z range from 800 to 4000) was acquired, and then the top 40 ions were detected by MS/MS.

Protein identification {#Sec6}
----------------------

Protein identification was performed with the ProteinPilot™ software (version 4.0.1; AB SCIEX). Each MS/MS spectrum was searched against a database (2017_03 released UniProtKB/Swiss-Prot human database, 20,183 entries) and a decoy database for FDR analysis (programmed in the software). The search parameters were as follows: trypsin enzyme; maximum allowed missed cleavages 1; Carbamidomethyl cysteine; biological modifications programmed in the algorithm. Proteins with high-confidence (FDR \< 0.01) were considered as positively identified proteins.

Bioinformatics {#Sec7}
--------------

The gene ontology enrichment analysis of HFF proteins were performed by using online bioinformatics tools of PANTHER (Protein ANalysis THrough Evolutionary Relationships) classification system (released 11.1, 2016--10-24) (<http://pantherdb.org/>) \[[@CR23]\] and DAVID (The Database for Annotation, Visualization and Integrated Discovery) bioinformatics resources 6.8 (<https://david.ncifcrf.gov/>) \[[@CR24]\]. Each protein was placed in only one category, and those with no annotation and supporting information were categorized as "Unknown". The pathway map of HFF proteins were achieved through KEGG: Kyoto Encyclopedia of Genes and Genomes (Release 81.0, 2017--01-01) (<http://www.kegg.jp>) \[[@CR25]\]. The protein-protein interaction network for the HFF proteins was annotated using the STRING (search tool for recurring instances of neighbouring genes) database (released 10.0, 2016--04--16) (<http://string-db.org/>) \[[@CR26]\]. The venn diagram was drawn through a online software "Calculate and draw custom Venn diagrams" (<http://bioinformatics.psb.ugent.be/webtools/>Venn/).

Western blot analysis {#Sec8}
---------------------

According to the method described previously \[[@CR27], [@CR28]\], 50 μg HFF protein were separated by a 12% SDS-PAGE gel and then electronically transferred onto a nitrocellulose membrane. The resultant membrane was blocked with 5% (*w*/*v*) skimmed milk for 1 h at 37 °C, and then was incubated with the primary antibody (Abcam, Cambridge, USA, diluted 1:2000) at 4 °C overnight. After washing with TBST for three times, the membranes were incubated with horse-radish peroxidase-conjugated secondary antibody (diluted 1:5000, Zhong-Shan Biotechnology, Beijing, China) at room temperature for 1 h. The immunoreactive proteins was visualized by enhanced chemiluminescence detection reagents (Pierce, Rockford, IL, USA) (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Results {#Sec9}
=======

Identification of high-confidence HFF proteome by dual RP-HPLC coupled with MALDI TOF/TOF mass spectrometry.

A peptide sequencing strategy was applied by using two-dimensional chromatography-MALDI TOF/TOF mass spectrometry. We employed high pH (pH 10) reverse phase liquid chromatography to decrease the complexity of the tryptic digest of the HFF proteins, and collected 28 fractions. Then each fraction was further separated by low pH (pH 3) reverse phase liquid chromatography, and spotted on the plate using the Tempo™ LC-MALDI Spotting System. After sequencing by a 5800 MALDI TOF/TOF mass spectrometry, the resultant spectra were analyzed by ProteinPilot™ software by searching the reviewed Swiss-Prot human database (20,183 sequences, 2017_03 released). A total of 219 unique high-confidence (FDR \< 0.01) proteins were identified by two replicates (Table [1](#Tab1){ref-type="table"}). Experiment 1 and 2 identified 188 with 2747 unique peptides and 179 proteins with 2800 unique peptides, respectively. 148 common proteins were shared between the two experiments. Figure [1](#Fig1){ref-type="fig"} showed representative MS/MS spectra of peptides from the identified HFF proteins. The m/z of precursor (Fig. [2c](#Fig2){ref-type="fig"}) was over 2500, and almost all b-ions and y-ions were still obtained based on a 5800 MALDI TOF/TOF mass spectrometry.Table 1A list of 219 identified high-confidence HFF proteins from women underwent successful IVF by LC MALDI TOF/TOF mass spectrometry (FDR \< 0.01)NoSwissProt ACName protein descriptionGene NameMolecular Weightexperiment 1experiment 2Coverage(%)Matched Peptides numberCoverage(%)Matched Peptides number1P43652AfaminAFM69,06931.91035.7102P02763Alpha-1-acid glycoprotein 1ORM123,51240.81740.8153P19652Alpha-1-acid glycoprotein 2ORM223,60345.81553.2154P01011Alpha-1-antichymotrypsinSERPINA347,651531544.2165P01009Alpha-1-antitrypsinSERPINA146,73762.78664.4766P04217Alpha-1B-glycoproteinA1BG54,25439.81748.5197P08697Alpha-2-antiplasminSERPINF254,56629.1947.1118P02765Alpha-2-HS-glycoproteinAHSG39,32542.81455.9189P01023Alpha-2-macroglobulinA2M163,29146.84747.44610P48728Aminomethyltransferase, mitochondrialAMT43,9462.21\--11P01019AngiotensinogenAGT53,15437.71425.81112C9JTQ0Ankyrin repeat domain-containing protein 63ANKRD6339,620151\--13P01008Antithrombin-IIISERPINC152,60261.92154.72414P02647Apolipoprotein A-IAPOA130,77873.86782.46915P02652Apolipoprotein A-IIAPOA211,17570964916P06727Apolipoprotein A-IVAPOA445,39967.22463.12517P02654Apolipoprotein C-IAPOC1933226.5337.4318P02655Apolipoprotein C-IIAPOC211,28439.6250.5319P02656Apolipoprotein C-IIIAPOC310,85234.3251.5620P05090Apolipoprotein DAPOD21,27624.9328.6321P02649Apolipoprotein EAPOE36,15443.2643.5422Q13790Apolipoprotein FAPOF35,399\--8123O95445Apolipoprotein MAPOM21,25326.6230.3224Q9H2U1ATP-dependent RNA helicase DHX36DHX36114,760\--17.9125O75882AttractinATRN158,537151\--26P98160Basement membrane-specific heparan sulfate proteoglycan core proteinHSPG2468,83030.843314627P02749Beta-2-glycoprotein 1APOH38,298511541.51628Q96KN2Beta-Ala-His dipeptidaseCNDP156,70618.91\--29P43251BiotinidaseBTD61,1339.2214.2130Q7L273BTB/POZ domain-containing protein KCTD9KCTD942,567\--30.1131P04003C4b-binding protein alpha chainC4BPA67,03311.9227432Q96IY4Carboxypeptidase B2CPB248,42413216.1233P22792Carboxypeptidase N subunit 2CPN260,557\--10.8234Q9ULM6CCR4-NOT transcription complex subunit 6CNOT663,307\--2.3135Q8N8E3Centrosomal protein of 112 kDaCEP112112,74917.41\--36Q5SW79Centrosomal protein of 170 kDaCEP170175,293\--5.9137P00450CeruloplasminCP122,20559.64758.15838O14647Chromodomain-helicase-DNA-binding protein 2CHD2211,344\--12139P10909ClusterinCLU52,49541.41450.11240P00740Coagulation factor IXF951,77815.21\--41P00742Coagulation factor XF1054,73224.6114.1142P00748Coagulation factor XIIF1267,79229.9420.8443Q5TID7Coiled-coil domain-containing protein 181CCDC18160,103\--7.9144P02746Complement C1q subcomponent subunit BC1QB26,72220.2118.6145Q9NZP8Complement C1r subcomponent-like proteinC1RL53,4988.616.2146P06681Complement C2C283,26821.5422.7647P01024Complement C3C3187,14867.112174.111948P0C0L4Complement C4-AC4A192,78546.65354.86649P0C0L5Complement C4-BC4B192,75146.352536650P01031Complement C5C5188,30520.3727.11251P13671Complement component C6C6104,78626625.5652P10643Complement component C7C793,51835.2823.1553P07357Complement component C8 alpha chainC8A65,16324.8523.5454P07358Complement component C8 beta chainC8B67,04737.1437.2655P07360Complement component C8 gamma chainC8G22,27748.5748556P02748Complement component C9C963,17336.5835.81057P00751Complement factor BCFB85,53341.42051.42558P08603Complement factor HCFH139,09655.44356.94559Q03591Complement factor H-related protein 1CFHR137,65133.9227.3560P05156Complement factor ICFI65,75031.1731.7561P08185Corticosteroid-binding globulinSERPINA645,14119.5317.3262Q9UBG0C-type mannose receptor 2MRC2166,6743.21\--63P01034Cystatin-CCST315,79922.61\--64P30876DNA-directed RNA polymerase II subunit RPB2POLR2B133,897\--10.7165Q8NHS0DnaJ homolog subfamily B member 8DNAJB825,68616.81\--66Q96DT5Dynein heavy chain 11, axonemalDNAH11520,369\--9.8167Q9C0C9E2 ubiquitin-conjugating enzymeUBE2O141,293\--3.9168O95071E3 ubiquitin-protein ligase UBR5UBR5309,3527.61\--69A4FU69EF-hand calcium-binding domain-containing protein 5EFCAB5173,4048.11\--70Q16610Extracellular matrix protein 1ECM160,67420.7211.5271Q9UGM5Fetuin-BFETUB42,05512.8118.3172P02671Fibrinogen alpha chainFGA94,97344.84047.64473P02675Fibrinogen beta chainFGB55,92872.15368.64274P02679Fibrinogen gamma chainFGG51,51269.136683475P02751FibronectinFN1262,62530.33331.23476Q08380Galectin-3-binding proteinLGALS3BP65,33122.9128.7477P06396GelsolinGSN85,69843.91643.62078P07093Glia-derived nexinSERPINE244,00234.7428.6379P22352Glutathione peroxidase 3GPX325,55216.4227180Q7Z4J2Glycosyltransferase 6 domain-containing protein 1GLT6D136,2742.61\--81P0CG08Golgi pH regulator BGPR89B52,917\--7.7182P00738HaptoglobinHP45,20561.12658.62383P00739Haptoglobin-related proteinHPR39,03044.310\--84Q9Y6N9HarmoninUSH1C62,2117.81\--85P69905Hemoglobin subunit alphaHBA1/HBA215,258\--28.2186P68871Hemoglobin subunit betaHBB15,99843.5252.4187P02790HemopexinHPX51,67655.84476.45088P05546Heparin cofactor 2SERPIND157,07121634.9689Q04756Hepatocyte growth factor activatorHGFAC70,6825.31\--90P04196Histidine-rich glycoproteinHRG59,578331537.91891O43365Homeobox protein Hox-A3HOXA346,3696.51\--92P78426Homeobox protein Nkx-6.1NKX6--137,84916.41\--93Q14520Hyaluronan-binding protein 2HABP262,67215.4211.8394P0DOX2Immunoglobulin alpha-2 heavy chainN/A48,93539.11440.91295P0DOX3Immunoglobulin delta heavy chainN/A56,22419.9123.4196P0DOX4Immunoglobulin epsilon heavy chainN/A60,3238.4215.7297P0DOX5Immunoglobulin gamma-1 heavy chainN/A49,33070.614471.912398P01876Immunoglobulin heavy constant alpha 1IGHA137,65542.82348.21699P01859Immunoglobulin heavy constant gamma 2IGHG235,90174.910469.992100P01860Immunoglobulin heavy constant gamma 3IGHG341,28772.46978.365101P01861Immunoglobulin heavy constant gamma 4IGHG435,94179.810168.885102P01871Immunoglobulin heavy constant muIGHM49,44033.11034.712103A0A0C4DH31Immunoglobulin heavy variable 1--18IGHV1--1812,82053748.79104P23083Immunoglobulin heavy variable 1--2IGHV1--213,08547.96\--105A0A0C4DH33Immunoglobulin heavy variable 1--24IGHV1--2412,82438.5238.53106A0A0C4DH29Immunoglobulin heavy variable 1--3IGHV1--313,00838.53\--107A0A0A0MS14Immunoglobulin heavy variable 1--45IGHV1--4513,5089.42\--108P01743Immunoglobulin heavy variable 1--46IGHV1--4612,933\--32.55109P01742Immunoglobulin heavy variable 1--69IGHV1--6912,659\--34.25110P01762Immunoglobulin heavy variable 3--11IGHV3--1112,90938.51053.911111P01766Immunoglobulin heavy variable 3--13IGHV3--1312,50660.36\--112A0A0B4J1V0Immunoglobulin heavy variable 3--15IGHV3--1512,92655.5842.97113P01764Immunoglobulin heavy variable 3--23IGHV3--2312,58260.71554.710114A0A0B4J1X8Immunoglobulin heavy variable 3--43IGHV3--4313,077\--34.86115A0A0A0MS15Immunoglobulin heavy variable 3--49IGHV3--4913,05647.1350.43116A0A075B6Q5Immunoglobulin heavy variable 3--64IGHV3--6412,89159.3218.61117A0A0C4DH42Immunoglobulin heavy variable 3--66IGHV3--6612,69861.21455.210118P01780Immunoglobulin heavy variable 3--7IGHV3--712,94376.91477.812119A0A0B4J1Y9Immunoglobulin heavy variable 3--72IGHV3--7213,20355.59\--120A0A0B4J1V6Immunoglobulin heavy variable 3--73IGHV3--7312,858583584121P01782Immunoglobulin heavy variable 3--9IGHV3--912,94551.7851.79122P06331Immunoglobulin heavy variable 4--34IGHV4--3413,815\--38.24123P01824Immunoglobulin heavy variable 4--39IGHV4--3913,91719.24\--124A0A0C4DH38Immunoglobulin heavy variable 5--51IGHV5--5112,67566.7950.48125P01834Immunoglobulin kappa constantIGKC11,76588.85092.537126P0DOX7Immunoglobulin kappa light chainN/A23,37961.25262.639127P04430Immunoglobulin kappa variable 1--16IGKV1--1612,618\--34.22128A0A075B6S5Immunoglobulin kappa variable 1--27IGKV1--2712,712478658129P01594Immunoglobulin kappa variable 1--33IGKV1--3312,84849.6542.74130P01602Immunoglobulin kappa variable 1--5IGKV1--512,78230.8330.86131A0A0C4DH72Immunoglobulin kappa variable 1--6IGKV1--612,697474475132A0A0C4DH69Immunoglobulin kappa variable 1--9IGKV1--912,71574.4544.45133P01611Immunoglobulin kappa variable 1D-12IGKV1D-1212,62044.4549.67134A0A0B4J2D9Immunoglobulin kappa variable 1D-13IGKV1D-1312,56913.71\--135A0A075B6S4Immunoglobulin kappa variable 1D-17IGKV1D-1712,83528.2143.62136P04432Immunoglobulin kappa variable 1D-39IGKV1D-3912,73747647.96137P06310Immunoglobulin kappa variable 2--30IGKV2--3013,18550563.37138P01615Immunoglobulin kappa variable 2D-28IGKV2D-2812,95733.3540.85139A0A075B6S2Immunoglobulin kappa variable 2D-29IGKV2D-2913,143\--20.85140P01614Immunoglobulin kappa variable 2D-40IGKV2D-4013,31037.2637.25141P04433Immunoglobulin kappa variable 3--11IGKV3--1112,57554.81649.610142P01624Immunoglobulin kappa variable 3--15IGKV3--1512,49642.6950.48143P01619Immunoglobulin kappa variable 3--20IGKV3--2012,55770.71670.714144A0A087WSY6Immunoglobulin kappa variable 3D-15IGKV3D-1512,53442.61056.58145A0A0C4DH25Immunoglobulin kappa variable 3D-20IGKV3D-2012,51564.71064.78146P06312Immunoglobulin kappa variable 4--1IGKV4--113,38034.71040.56147A0M8Q6Immunoglobulin lambda constant 7IGLC711,25454.71353.810148A0A0B4J1U3Immunoglobulin lambda variable 1--36IGLV1--3612,47813.7113.71149P01703Immunoglobulin lambda variable 1--40IGLV1--4012,30221.22\--150P01700Immunoglobulin lambda variable 1--47IGLV1--4712,28454.7439.33151P01706Immunoglobulin lambda variable 2--11IGLV2--1112,64422.73\--152A0A075B6K4Immunoglobulin lambda variable 3--10IGLV3--1012,441404403153P01714Immunoglobulin lambda variable 3--19IGLV3--1912,04250242.91154P80748Immunoglobulin lambda variable 3--21IGLV3--2112,44635.93\--155P01717Immunoglobulin lambda variable 3--25IGLV3--2512,011\--43.83156P01721Immunoglobulin lambda variable 6--57IGLV6--5712,56620.52\--157P0DOX8Immunoglobulin lambda-1 light chainN/A22,83044.42344.420158P15814Immunoglobulin lambda-like polypeptide 1IGLL122,963235235159P35858Insulin-like growth factor-binding protein complex acid labile subunitIGFALS66,03523.1427.46160P16144Integrin beta-4ITGB4202,1674.91\--161P19827Inter-alpha-trypsin inhibitor heavy chain H1ITIH1101,38933.62033.725162P19823Inter-alpha-trypsin inhibitor heavy chain H2ITIH2106,46335.91842.620163Q06033Inter-alpha-trypsin inhibitor heavy chain H3ITIH399,8495.2115.51164Q14624Inter-alpha-trypsin inhibitor heavy chain H4ITIH4103,35738.4234726165Q15811Intersectin-1ITSN1195,422\--9.91166P29622KallistatinSERPINA448,54226.54235167Q92764Keratin, type I cuticular Ha5KRT3550,361\--16.71168P13645Keratin, type I cytoskeletal 10KRT1058,8275.81\--169P04264Keratin, type II cytoskeletal 1KRT166,03923.63302170P01042Kininogen-1KNG171,95753.7254123171P02750Leucine-rich alpha-2-glycoproteinLRG138,17821.6427.15172P18428Lipopolysaccharide-binding proteinLBP53,38414.8113.31173P51884LumicanLUM38,42930.2327.83174P14174Macrophage migration inhibitory factorMIF12,47618.32\--175P01033Metalloproteinase inhibitor 1TIMP123,17118.8234.82176Q7Z5P9Mucin-19MUC19805,2534.31\--177P35579Myosin-9MYH9226,532\--15.81178Q96PD5N-acetylmuramoyl-L-alanine amidasePGLYRP262,21726729.36179A6NHN0Otolin-1OTOL149,42215.31\--180P04180Phosphatidylcholine-sterol acyltransferaseLCAT49,57815.52\--181P36955Pigment epithelium-derived factorSERPINF146,31222.3517.95182P03952Plasma kallikreinKLKB171,37023626.56183P05155Plasma protease C1 inhibitorSERPING155,15434.8933.216184P05154Plasma serine protease inhibitorSERPINA545,67513.63\--185P00747PlasminogenPLG90,569633058.832186Q96GD3Polycomb protein SCMH1SCMH173,3544.71\--187Q8WUM4Programmed cell death 6-interacting proteinPDCD6IP96,023\--14.11188P46013Proliferation marker protein Ki-67MKI67358,69411.9121.81189P15309Prostatic acid phosphataseACPP44,56625.1417.92190P02760Protein AMBPAMBP38,99938.91142.112191Q9UK55Protein Z-dependent protease inhibitorSERPINA1050,70715.5218.92192Q96PF1Protein-glutamine gamma-glutamyltransferase ZTGM779,941\--7.51193P00734ProthrombinF270,03759.83362.431194P02753Retinol-binding protein 4RBP423,01040.31155.713195O94885SAM and SH3 domain-containing protein 1SASH1136,653\--10.31196P04279Semenogelin-1SEMG152,13130.5532.35197Q02383Semenogelin-2SEMG265,444213185198P57059Serine/threonine-protein kinase SIK1SIK184,902\--7.31199P02787SerotransferrinTF77,06471.414379.4185200P02768Serum albuminALB69,36789.360791.3550201P35542Serum amyloid A-4 proteinSAA414,74730249.26202P02743Serum amyloid P-componentAPCS25,38726.5525.15203P27169Serum paraoxonase/arylesterase 1PON139,73124.5719.25204P04278Sex hormone-binding globulinSHBG43,77918.7421.93205P09486SPARCSPARC34,632\--5.31206Q6N022Teneurin-4TENM4307,9575.31\--207P05452TetranectinCLEC3B22,53722.8230.22208P05543Thyroxine-binding globulinSERPINA746,32514.5123.62209Q8WZ42TitinTTN3,816,03010.61\--210P21675Transcription initiation factor TFIID subunit 1TAF1212,677\--71211Q66K66Transmembrane protein 198TMEM19839,4752.522.51212P02766TransthyretinTTR15,88769.41269.419213P13611Versican core proteinVCAN372,820\--5.22214P02774Vitamin D-binding proteinGC52,96463.92960.328215P04070Vitamin K-dependent protein CPROC52,071\--2.21216P07225Vitamin K-dependent protein SPROS175,12312.62\--217P04004VitronectinVTN54,30632.61132.215218Q6PF04Zinc finger protein 613ZNF61370,1436.61\--219P25311Zinc-alpha-2-glycoproteinAZGP134,25952.7145217 Fig. 1Identification of HFF proteins by LC MALDI TOF/TOF MS Spectra. The MS/MS map (**a**, **b**) marked with b ions and y ions for vitamin D-binding protein identification. The sequences of precursor at m/z 2053.8506 and 2353.9646 were analyzed by MS/MS to be GQELCADYSENTFTEYK and SYLSMVGSCCTSASPTVCFLK and the protein identified as vitamin D-binding protein. The MS/MS map (**c**, **d**) marked with b ions and y ions for retinol-binding protein 4 identification. The sequences of precursor at m/z 2692.0667 and 1197.6047 were analyzed by MS/MS to be GNDDHWIVDTDYDTYAVQYSCR and YWGVASFLQK and the protein identified as retinol-binding protein 4 Fig. 2Pie diagrams of the proportion of HFF proteins categorized by GO classifications based on their (**a**) molecular function, (**b**) subcellular localization, (**c**) biological process

Bioinformatics analysis of the HFF proteome {#Sec10}
-------------------------------------------

The proteins identified by mass spectrometry were broadly placed into several GO categories on the basis of the PANTHER, DAVID and PubMed databases (Fig. [2](#Fig2){ref-type="fig"}). Based on molecular function, the majority (31%) of proteins were related to immunity, whereas other involved protein functions were mainly complement and coagulation (17%), protease or inhibitor (14%), and transportation (10%) (Fig. [2a](#Fig2){ref-type="fig"}). Based on subcellular localization, the majority (64%) of the identified proteins located in extracellular region. Other main locations were extracellular matix (7%), nuleus (6%), and cytoskeleton (5%) (Fig. [2b](#Fig2){ref-type="fig"}). Based on biological process, the majority (28%) of proteins was related to developmental process, and the next prevalence was immunological system process (26%). The other groups were involved into protein metabolic process (12%), reproduction (5%), lipid metabolic process (3%), and transportation (2%) (Fig. [2c](#Fig2){ref-type="fig"}).

KEGG pathway analysis was performed to map HFF protein interactions, Pathways associated with complement and coagulation cascades (P_Value = 5.8E-52), [vitamin digestion and absorption](https://david.ncifcrf.gov/kegg.jsp?path=hsa04977$Vitamin%20digestion%20and%20absorption&termId=550028858&source=kegg) (P_Value = 0.023), and (P_Value = 0.066) were significantly enriched. Figure [3](#Fig3){ref-type="fig"} showed the complement and coagulation cascades pathway which included 17 (7.8%) and 21 (9.6%) highlighted HFF proteins in coagulation cascade and complement cascade, respectively.Fig. 3Presentative Network of protein HSPG2 in the identified HFF proteome. A total of 21 genes are connected with 105 paired relationships annotated by STRING database. The relationships among proteins were derived from evidence that includes textmining, co-expression, protein homology, gene neighborhood, from curated databases, experimentally determined, gene fusions, and gene co-occurrence (as shown in the legend with different color)

A protein-protein interaction network was constructed by retrieving the STRING database. 151 proteins were in connection with other proteins, which lead to 738 paired relationships. As an example, 21 of 151 proteins related to basement membrane-specific heparan sulfate proteoglycan core protein (HSPG) was chosen, and 105 paired relationships were connected (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4The KEGG pathway of complement and coagulation cascades with the identified HFF proteins highlighted. Generated by the KEGG online (hsa04610), this diagram showed the roles if HFF proteins in complement (*Red*) and coagulation cascades (*Blue*)

Comparison of present HFF proteome, the previous reported HFF proteome and human plasma proteome {#Sec11}
------------------------------------------------------------------------------------------------

To disclose the overlap of the HFF proteomes between different labs and to explore the orign of the HFF proteins, the previous reported HFF proteins \[[@CR14]\] and the human plasma proteome \[[@CR29]\] were selected, whose protein identification criteria were both at a false discovery rate (FDR) of 1%. The results reflected the overlap of our HFF proteins and the previously reported HFF proteins with human plasma proteins (Fig. [5](#Fig5){ref-type="fig"}). A total of 49% proteins in our HFF data were common to the previous HFF data. Compared with human plasma proteins, 69% proteins from our HFF data and 64% proteins from previous HFF data were common to human plasma proteins.Fig. 5Venn diagram of the overlap of HFF and human plasma protein datasets. Distribution of our present findings or the previously reported HFF proteins (Aditi S. Ambekar et al. 2013) and their overlap with those reported in human plasma (Terry Farrah et al. 2011)

Western blotting analysis {#Sec12}
-------------------------

To verify the confidence of the proteome data, the expression patterns of 3 HFF proteins (retinol-binding protein 4, vitamin D-binding protein and lactotransferrin) from 10 women undergoing successful IVF were analyzed by western blotting (Fig. [6](#Fig6){ref-type="fig"}). Those three proteins could be detected in all 10 HFF samples. Compared with retinol-binding protein 4 and lactotransferrin, the expression of vitamin D-binding protein was relatively constant level in the HFF of ten women.Fig. 6Immunoblot analysis of retinol-binding protein 4, vitamin D-binding protein and lactotransferrin in 10 HFF samples of women underwent successful IVF. Protein lysates prepared from 10 HFF samples were examined by immunoblots using specific antibodies recognizing the retinol-binding protein 4(23 kDa), vitamin D-binding protein (53 kDa) and lactotransferrin (78 kDa)

Discussion {#Sec13}
==========

Proteomics has been carried out to discover HFF biomarkers for decades, and liquid chromatography coupled with ion trap MS became widely available with the development of high-throughput sequencing. The identification of HFF proteins from women with and without endometriosis was performed using ESI MS/MS \[[@CR30]\]. Nanoflow LC-MS/MS combined with TMT labeling was used to identify HFF biomarkers from women undergoing IVF/ICSI treatment with or without folic acid supplement \[[@CR31]\]. Another advance LTQ Orbitrap system coupled with LC was also applied to comparing HFF proteins between fertilized oocytes and non-fertilized oocytes from the same patient \[[@CR32]\]. Based on sample pre-fractionation using microscale in-solution isoelectric focusing (IEF), capillary electrophoresis (CE) coupled off-line to matrix assisted laser desorption/ionization time of flight tandem mass spectrometry (MALDI TOF MS/MS) identified 73 unique proteins \[[@CR33]\]. Hanrieder and co-workers \[[@CR34]\] utilized a proteomic strategy of IEF and reversed-phase nano-liquid chromatography coupled to MALDI TOF/TOF mass spectrometry to identify 69 proteins related to controlled ovarian hyper stimulation (COH) during IVF. However, limited proteins were identified which delayed the research of HFF protein networks.

In the present work, a dual RP-HPLC coupled with MALDI TOF/TOF mass spectrometry was performed to identify HFF protein profiles associated with successful IVF, and 219 unique high-confidence (FDR \< 0.01) HFF proteins were identified by searching the reviewed Swiss-Prot human database (20,183 sequences). Meanwhile, the new strategy indicated that the effective dual reverse LC pre-fractionation \[[@CR21]\] could identify more HFF proteins.

Ambekar and co-workers carried out SDS-PAGE, OFFGEL and SCX-based separation followed by LC--MS/MS (an LTQ-Orbitrap Velos MS) to identify 480 HFF proteins with high confidence (FDR \< 0.01) \[[@CR14]\]. A comparison with our results and these data showed that more than 50% proteins in present study were not found in previous dataset (Additional file [2](#MOESM2){ref-type="media"}: Figure S1), which indicated that the data from different MS platforms were complementary. Retinol-binding protein 4 and vitamin D-binding protein were verified by western blotting, and the results showed they were all expressed in the 10 HFF samples. Lactotransferrin was uniquely included in Ambekar's data, and was also successfully detected by western blotting in our study. This result not only testified the good quality of Ambekar's data, but also facilitated to integrate the data from different MS platform in the future. Interestingly, more than 60% of combined HFF proteins from our data and Ambekar's data were found in the reported human plasma data \[[@CR29]\]. HFF was a complex mixture, and the content of HFF mainly originates from the transfer of blood plasma constituents via theca capillaries, and the secretion of granulosa and thecal cells \[[@CR5]\]. From the above contrast, we considered the transfer of plasma proteins was the major source of HFF, and the alternative permeability of theca capillaries would change the HFF compositions which inevitably impaired the oocyte quality, and even caused unsuccessful IVF outcome.

Bioinformatics analysis showed that 5% HFF proteins were involved in lipid metabolism and transport process. It has been reported that ageing could decrease apolipoprotein A1 and apolipoprotein CII, while increase apolipoprotein E, which were associated with the decline in production of mature oocytes and the decline in fertility potential \[[@CR35]\]. Preconception folic acid supplementation upregulated apolipoprotein A-I and apolipoprotein C-I of the HDL pathway in human follicular fluid, which increased embryo quality and IVF/ICSI treatment outcome \[[@CR30]\]. In our HFF data, apolipoprotein A-I, apolipoprotein A-II, apolipoprotein A-IV, apolipoprotein C-I, apolipoprotein C-II, apolipoprotein C-III, apolipoprotein D, apolipoprotein E, apolipoprotein F, and apolipoprotein M were all found, which indicated that those apolipoproteins were related to cholesterol homeostasis and steroidogenesis and played important roles in the maintenance of oocyte maturation microenvironment.

Pathway analysis showed that complement and coagulation cascades were the most prominent pathways (P_Value = 5.8E-52). Complement cascade promoted coagulation through the inhibition of fibrinolysis, and coagulation cascade in return amplified complement activation. Complement cross_talked with coagulation in a reciprocal way \[[@CR36]\]. For example, plasmin, thrombin, elastase and plasma kallikrein could activate C3 \[[@CR37]\]. Coagulation activation factor XII could cleave C1 to activate the classical complement pathway \[[@CR38]\]. And thrombin could also directly cleave C5 to generate active C5a \[[@CR39]\]. Among our HFF proteins, components (F12, KLKB1, PLG, KNG1, F9, F10, SERPINC1, SERPIND1, SERPINA5, F2, PROS1, PROC, SERPINA1, SERPINF2, A2M, CPB2, and FGA) of extrinsic pathway and intrinsic pathway in coagulation cascade and those (FH, FI, FB, C3, C1qrs, SERPING1, C2, C4, C4BP, C5, C6, C7, C8A, C8B, C8G, C9, FGA, FGG, PLG, FGB, F10) of alternative pathway, classical pathway, and lectin pathway in complement cascade were all identified. During follicle development and ovulation, coagulation system in HFF contributed to HFF liquefaction, fibrinolysis and the breakdown of follicle wall \[[@CR40], [@CR41]\]. Follicle development had been hypothesized as the controlled inflammatory processes in 1994 \[[@CR42]\], and inappropriate complement activation was linked to abortion \[[@CR43]\]. Inhibition of complement activation improved angiogenesis failure and rescued pregnancies \[[@CR44]\]. The paired comparison of HFF with plasma showed C3, C4, C4a, and C9 as well as complement factor H and clusterin might contribute to the inhibition of complement cascade activity for women undergoing controlled ovarian stimulation for IVF \[[@CR45]\]. However there were still debates on the role of complement cascade in IVF. Physiologic complement activation protected the host against infection in normal pregnancy \[[@CR46]\]. In comparison with those non-fertilized oocytes, C3 was more abundant in HFF from fertilized oocytes \[[@CR47]\]. In the course of IVF treatment, the functions of complement and coagulation cascade were very complicated during ovarian hyperstimulation. More works were still deserved in both mechanism research and clinical practice.

Based on the analysis of STRING, we discovered a profound HFF protein-protein interaction networks. 151 of 219 HFF proteins participated in the network with 738 paired relationships. Basement membrane-specific HSPG was found as a node, which was also a potential biomarker for oocyte maturation in HFF. HSPG was widely distributed on the surface of animal cells, and especially strongly expressed in granulosa cells. HSPG played a critical role in controlling inflammation control through binding and activating antithrombin III during folliculogenesis \[[@CR48]\]. Women with PCOS showed HSPG defect in follicular development \[[@CR49]\], and on the contrary, HSPG was up-regulated in the fertilized-oocyte HFF \[[@CR32]\]. In the network, HSPG interacted with 20 of 219 HFF proteins, and constructed 105 paired relationships. We deduced that the loss of HSPG might affect the function of the whole network or more complicated interaction maps, which might cause subsequent failures of oocyte maturation, fertilization, and IVF treatment.

Conclusions {#Sec14}
===========

HFF had a natural advantage for the noninvasive prediction of oocyte quality and IVF treatment outcome. The present study would provide a new complementary dataset for better understanding of oocyte maturation, and also delineate a new networks and pathways involved into the folliculogenesis. Furthermore, those novel findings would facilitate to testify the potential biomarkers associated with oocyte quality and IVF outcome. In the future, international laboratory collaboration should be established to standardize and optimize experimental design, patient selection, HFF handling, analysis methods, data standard, and clinical verification, which will greatly promote basic research of reproductive medicine, and ultimately accelerate the clinical transformation.
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